California-Based Adjuvia Therapeutics Scores $8M in Seed Funding

Adjuvia Therapeutics, a San Francisco, CA-based biotechnology company developing therapeutics to treat mitochondrial dysfunction and disease, raised $8M in a Seed financing series led by JLO Ventures.

The round also saw participation from Portfolia Ventures and experienced biopharmaceutical industry leaders.

The funding will help the company progress ATI-105 through key clinical and regulatory milestones, beginning with an Investigational New Drug (IND) application later this summer.

Funding Snapshot

About Adjuvia Therapeutics

Founded in 2023, by Laura Hix Glickman, Adjuvia Therapeutics is a biotechnology company focused on developing therapies for mitochondrial dysfunction and disease. The company employs a multi pronged therapeutic approach that simultaneously targets oxidative stress, chronic inflammation and organ degeneration to repair mitochondrial damage.

Read More:Canada-based Liquid Interactive Raises $700K in Pre-Seed Funding

Its lead candidate, ATI-105, is a proprietary blood-brain barrier (BBB)-penetrant lipid nanoparticle formulation of a novel astaxanthin molecule designed to deliver superior bioactivity and bioavailability. The therapy is being developed for rare mitochondrial diseases and has shown promising preclinical results.

Core offerings include:

• Therapies for mitochondrial diseases.
• Oral medicines that help repair mitochondria.
• Lipid nanoparticle drug delivery technology.
• Treatments for rare neurodegenerative and mitochondrial disorders.

Core Technologies / Products / Services